Intra Cellular Therapies Inc Quick Ratio (ITCI) starting from the fourth quarter 2024 to fourth quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Intra cellular Therapies Inc   (NASDAQ: ITCI)

Intra Cellular Therapies Inc 's Quick Ratio

ITCI's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2024, Quick Ratio fell to 4.87 below Intra Cellular Therapies Inc average.

Within Major Pharmaceutical Preparations industry 184 other companies have achieved higher Quick Ratio than Intra Cellular Therapies Inc in fourth quarter 2024. While Quick Ratio total ranking in the fourth quarter 2024 has deteriorated compared to the prior quarter from 415 to 596.

Explain Quick Ratio?
How much Cash & cash equivalents ITCI´s has?
What are ITCI´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ITCI Quick Ratio (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4
Y / Y Current Liabilities Change 66.5 % 61.13 % 75.69 % 69.38 % 48.43 %
Y / Y Cash & cash equivalent Change 101.04 % 104.16 % 99.45 % -11.71 % -15.87 %
Quick Ratio MRQ 4.87 6.06 6.32 3.53 4.03
ITCI's Total Ranking # 596 # 415 # 467 # 442 # 207
Seq. Current Liabilities Change 23.83 % 2.68 % 20.01 % 9.11 % 19.84 %
Seq. Cash & cash equivalent Change -0.55 % -1.6 % 115.07 % -4.48 % 1 %



Quick Ratio fourth quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 185
Healthcare Sector # 298
Overall Market # 596


Quick Ratio Statistics
High Average Low
75.87 17.07 0
(Dec 31 2015)   (Jun 30 2013)




Financial Statements
Intra Cellular Therapies Inc 's Current Liabilities $ 206 Millions Visit ITCI's Balance sheet
Intra Cellular Therapies Inc 's Cash & cash equivalent $ 1,001 Millions Visit ITCI's Balance sheet
Source of ITCI's Sales Visit ITCI's Sales by Geography


Cumulative Intra Cellular Therapies Inc 's Quick Ratio

ITCI's Quick Ratio for the trailling 12 Months

ITCI Quick Ratio

 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth 67.81 % 63.75 % 57.45 % 45.89 % 37.18 %
Y / Y Cash & cash equivalent TTM Growth 71.66 % 40.56 % 39.95 % 47.37 % 118.73 %
Quick Ratio TTM 5.25 5.12 4.76 4.36 5.13
Total Ranking TTM # 2251 # 2493 # 165 # 2595 # 334
Seq. Current Liabilities TTM Growth 14.01 % 12.04 % 15.37 % 13.86 % 11.26 %
Seq. Cash & cash equivalent TTM Growth 16.75 % 20.63 % 25.77 % -3.09 % -4.4 %

Quick ratio ranking by company, industry and sector >> Back to ITCI Financial Strength Comparisons >> Go to Compare ITCI Quick Ratio to its Competitors

On the trailing twelve months basis ITCI Cash & cash equivalent more than doubled by 101.04 % in Q4 2024 year on year, faster than Current Liabilities, this led to increase in in Intra Cellular Therapies Inc 's Quick Ratio to 5.25, Quick Ratio remained below ITCI average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 254 other companies have achieved higher Quick Ratio than Intra Cellular Therapies Inc . While Quick Ratio overall ranking has improved so far to 2251, from total ranking during the twelve months ending third quarter 2024 at 2493.

Explain Quick Ratio?
How much Cash & cash equivalents ITCI´s has?
What are ITCI´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 255
Healthcare Sector # 557
Within the Market # 2251


trailing twelve months Quick Ratio Statistics
High Average Low
47.14 14.3 2.9
(Mar 31 2016)   (Sep 30 2022)




Companies with similar Quick Ratio in the quarter ending Dec 31 2024, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2024 MRQ Cash & cash equivalentDec 31 2024 MRQ Current Liabilities
Genmab A  13.36 $ 1,380.000  Millions$ 103.267  Millions
Savara Inc   13.33 $ 196.327  Millions$ 14.724  Millions
Spruce Biosciences Inc   13.29 $ 38.753  Millions$ 2.917  Millions
Rezolute Inc   13.21 $ 126.874  Millions$ 9.606  Millions
Bicycle Therapeutics Plc  13.08 $ 879.520  Millions$ 67.230  Millions
Aardvark Therapeutics Inc   12.94 $ 73.663  Millions$ 5.693  Millions
Praxis Precision Medicines Inc   12.94 $ 469.572  Millions$ 36.291  Millions
Bioage Labs Inc   12.76 $ 354.349  Millions$ 27.775  Millions
Palvella Therapeutics Inc   12.74 $ 83.602  Millions$ 6.564  Millions
Arrivent Biopharma inc   12.67 $ 218.863  Millions$ 17.274  Millions
Corbus Pharmaceuticals Holdings Inc   12.61 $ 149.062  Millions$ 11.818  Millions
Maplight Therapeutics Inc   12.60 $ 190.717  Millions$ 15.142  Millions
Lixte Biotechnology Holdings Inc   12.48 $ 1.039  Millions$ 0.083  Millions
Verona Pharma Plc  12.45 $ 399.757  Millions$ 32.102  Millions
Verve Therapeutics Inc   12.22 $ 524.281  Millions$ 42.909  Millions
89bio Inc   12.18 $ 439.955  Millions$ 36.129  Millions
Eledon Pharmaceuticals Inc   12.11 $ 140.178  Millions$ 11.577  Millions
Damora Therapeutics Inc   11.84 $ 14.175  Millions$ 1.197  Millions
Pmv Pharmaceuticals Inc   11.79 $ 169.454  Millions$ 14.370  Millions
Xbiotech Inc   11.43 $ 172.677  Millions$ 15.105  Millions
Veradermics Inc  11.25 $ 53.084  Millions$ 4.718  Millions
Satellos Bioscience Inc   11.19 $ 40.041  Millions$ 3.580  Millions
Ligand Pharmaceuticals Incorporated  10.99 $ 407.784  Millions$ 37.112  Millions
Benitec Biopharma Inc   10.97 $ 50.891  Millions$ 4.640  Millions
Immunome Inc   10.81 $ 217.303  Millions$ 20.106  Millions
Pliant Therapeutics Inc   10.71 $ 355.724  Millions$ 33.218  Millions
Ars Pharmaceuticals Inc   10.70 $ 314.022  Millions$ 29.360  Millions
Rallybio Corporation  10.50 $ 65.511  Millions$ 6.242  Millions
Acrivon Therapeutics Inc   10.43 $ 179.480  Millions$ 17.214  Millions
Olema Pharmaceuticals Inc   10.40 $ 434.086  Millions$ 41.758  Millions

Date modified: 2026-09-26T06:58:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.